4/A: Recursion Pharmaceuticals CEO Christopher Gibson Converts 100,000 Shares of Class B Common Stock to Class A

Christopher Gibson, CEO of Recursion Pharmaceuticals, converted 100,000 shares of Class B Common Stock to Class A Common Stock on June 5, 2024, according to a Form 4/A filing with the SEC.

Summary

• On June 5, 2024, Christopher Gibson, the CEO of Recursion Pharmaceuticals, converted 100,000 shares of Class B Common Stock into Class A Common Stock.
• This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 27, 2023.
• The filing amends a previous filing on June 7, 2024, to correct the number of shares converted from 25,000 to 100,000.
• Following the transaction, Gibson directly owns 908,738 shares of Class A Common Stock and 6,326,700 derivative securities representing Class A Common Stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing an insider transaction. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about stock conversion.

Industry Context

This filing reflects insider transactions, which are common in publicly traded companies. Monitoring these transactions can provide insights into management's perspective on the company's value and future prospects.

Stakeholder Impact

• The conversion of shares may have a minor impact on shareholders due to the increased number of Class A shares outstanding.
• The transaction does not appear to have a direct impact on employees, customers, suppliers, or creditors.

Key Dates